A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia
This is a open label, phase Ib/II study. All patients are diagnosed with AML, Eastern Cooperative Oncology Group (ECOG) performance status 0-3. The purpose of this study is to evaluate the safety and efficacy of AK117 + azacitidine in subjects with AML.
Acute Myeloid Leukemia
DRUG: AK117|DRUG: Azacitidine
Composite complete remission rate （complete remission + complete remission with incomplete count recovery）, Number of participants achieving a complete remission (CR) and complete remission with incomplete hematologic recovery (CRi) per European LeukemiaNet (ELN) 2017 criteria., Approximately 6 months|Number of participants with adverse events (AEs), An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment., Up to approximately 2 years.
Rate of CR Without Minimal Residual Disease (CR MRD-), The rate of CR MRD- is the percentage of participants who achieve a CR MRD- as defined by investigators based on ELN 2017 criteria., Approximately 6 months|Duration of complete response (DoCR), The DoCR is measured from the time the assessment criteria are first met for CR (including CR MRD- and CR MRD+/unk) until the first date of AML relapse or death., Approximately 6 months|Overall Survival, The OS is measured from the date of treatment to the date of death from any cause., Up to death or end of study|Event-Free Survival (EFS), The EFS is defined as time from the date of treatment to the earliest date of documented relapse from complete remission (CR), treatment failure , or death from any cause., Up to end of study|Maximum observed concentration (Cmax) of AK117, Serum concentrations of AK117 in individual subjects at different time points after AK117 administration., Up to 2 years.|Anti-drug antibodies (ADA), Number of subjects with detectable anti-drug antibodies (ADA)., Up to 2 years.
This is a open label, phase Ib/II study. All patients are diagnosed with AML, Eastern Cooperative Oncology Group (ECOG) performance status 0-3. The purpose of this study is to evaluate the safety and efficacy of AK117 + azacitidine in subjects with AML.